CA2685147A1 - Auto-antibody markers of autoimmune disease - Google Patents
Auto-antibody markers of autoimmune disease Download PDFInfo
- Publication number
- CA2685147A1 CA2685147A1 CA002685147A CA2685147A CA2685147A1 CA 2685147 A1 CA2685147 A1 CA 2685147A1 CA 002685147 A CA002685147 A CA 002685147A CA 2685147 A CA2685147 A CA 2685147A CA 2685147 A1 CA2685147 A1 CA 2685147A1
- Authority
- CA
- Canada
- Prior art keywords
- auto
- ifn
- alpha
- antibodies
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 128
- 238000000034 method Methods 0.000 claims abstract description 299
- 238000012544 monitoring process Methods 0.000 claims abstract description 10
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims description 256
- 239000000427 antigen Substances 0.000 claims description 127
- 230000000694 effects Effects 0.000 claims description 92
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims description 83
- 210000002966 serum Anatomy 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 63
- 108010036781 Fumarate Hydratase Proteins 0.000 claims description 61
- 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 claims description 61
- 239000003795 chemical substances by application Substances 0.000 claims description 61
- 230000014509 gene expression Effects 0.000 claims description 60
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 claims description 59
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 claims description 57
- 101001112293 Homo sapiens Retinoic acid receptor alpha Proteins 0.000 claims description 48
- 239000003550 marker Substances 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 201000004681 Psoriasis Diseases 0.000 claims description 44
- 102100023433 RNA-binding protein RO60 Human genes 0.000 claims description 44
- 101000583692 Homo sapiens Pleckstrin homology-like domain family A member 1 Proteins 0.000 claims description 42
- 102100030887 Pleckstrin homology-like domain family A member 1 Human genes 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 42
- 101000582846 Homo sapiens Mediator of RNA polymerase II transcription subunit 22 Proteins 0.000 claims description 41
- 102100030223 Mediator of RNA polymerase II transcription subunit 22 Human genes 0.000 claims description 41
- 229940124597 therapeutic agent Drugs 0.000 claims description 41
- 206010025135 lupus erythematosus Diseases 0.000 claims description 40
- 101000685886 Homo sapiens RNA-binding protein RO60 Proteins 0.000 claims description 39
- 241000712461 unidentified influenza virus Species 0.000 claims description 39
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 38
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 38
- 102100033416 60S acidic ribosomal protein P1 Human genes 0.000 claims description 37
- 101000712357 Homo sapiens 60S acidic ribosomal protein P1 Proteins 0.000 claims description 37
- 102100027869 Moesin Human genes 0.000 claims description 36
- 102100026482 Tubulin-folding cofactor B Human genes 0.000 claims description 36
- 108010071525 moesin Proteins 0.000 claims description 36
- 101000980303 Homo sapiens 10 kDa heat shock protein, mitochondrial Proteins 0.000 claims description 32
- 108010059013 Chaperonin 10 Proteins 0.000 claims description 31
- 208000031713 Autosomal recessive spastic paraplegia type 20 Diseases 0.000 claims description 30
- 101000992387 Homo sapiens Oxysterol-binding protein-related protein 9 Proteins 0.000 claims description 30
- 102100032162 Oxysterol-binding protein-related protein 9 Human genes 0.000 claims description 30
- 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 claims description 30
- 101710091952 Tropomyosin alpha-3 chain Proteins 0.000 claims description 30
- 201000003397 Troyer syndrome Diseases 0.000 claims description 30
- 101710087831 Tubulin-folding cofactor B Proteins 0.000 claims description 30
- 102100039407 Pyrroline-5-carboxylate reductase 1, mitochondrial Human genes 0.000 claims description 29
- 102100033756 39S ribosomal protein L45, mitochondrial Human genes 0.000 claims description 28
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 28
- 101000733888 Homo sapiens 39S ribosomal protein L45, mitochondrial Proteins 0.000 claims description 28
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 28
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 28
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 28
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 claims description 26
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 claims description 26
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 claims description 26
- 206010033892 Paraplegia Diseases 0.000 claims description 25
- 102100030537 Spartin Human genes 0.000 claims description 25
- 101710015530 Spartin Proteins 0.000 claims description 25
- 208000032930 Spastic paraplegia Diseases 0.000 claims description 25
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 25
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 25
- FCEHFCFHANDXMB-UMEYXWOPSA-N tocosimplex Chemical compound OS(O)(=O)=O.C1N2CCCC[C@@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 FCEHFCFHANDXMB-UMEYXWOPSA-N 0.000 claims description 25
- 102000008013 Electron Transport Complex I Human genes 0.000 claims description 23
- 108010089760 Electron Transport Complex I Proteins 0.000 claims description 23
- 101000577853 Homo sapiens DNA mismatch repair protein Mlh1 Proteins 0.000 claims description 23
- 101000941884 Homo sapiens Leucine-rich repeat flightless-interacting protein 2 Proteins 0.000 claims description 23
- 101000979687 Homo sapiens Nuclear distribution protein nudE homolog 1 Proteins 0.000 claims description 23
- 102100032694 Leucine-rich repeat flightless-interacting protein 2 Human genes 0.000 claims description 23
- 201000002481 Myositis Diseases 0.000 claims description 23
- 102100023311 Nuclear distribution protein nudE homolog 1 Human genes 0.000 claims description 23
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 claims description 23
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 claims description 23
- 101710128188 Tropomyosin alpha-1 chain Proteins 0.000 claims description 23
- 206010047115 Vasculitis Diseases 0.000 claims description 23
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 claims description 23
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims description 23
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 claims description 23
- 201000000306 sarcoidosis Diseases 0.000 claims description 23
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims description 22
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims description 22
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims description 22
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 22
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims description 20
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 claims description 20
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims description 20
- 101710142338 Pyrroline-5-carboxylate reductase 1 Proteins 0.000 claims description 20
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 claims description 20
- 239000012190 activator Substances 0.000 claims description 20
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 claims description 19
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 claims description 19
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 claims description 19
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 claims description 19
- 102000042463 Rho family Human genes 0.000 claims description 19
- 108091078243 Rho family Proteins 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 15
- 230000009467 reduction Effects 0.000 claims description 15
- 101001078626 Homo sapiens Heat shock protein HSP 90-alpha A2 Proteins 0.000 claims description 14
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 claims description 14
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 claims description 14
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 claims description 13
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 claims description 13
- 239000003124 biologic agent Substances 0.000 claims description 13
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 12
- 229930002330 retinoic acid Natural products 0.000 claims description 12
- 229960001727 tretinoin Drugs 0.000 claims description 12
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims description 11
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims description 11
- 102100037686 Protein SSX2 Human genes 0.000 claims description 11
- 101710149284 Protein SSX2 Proteins 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 11
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims description 10
- 108030001720 Bontoxilysin Proteins 0.000 claims description 10
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims description 10
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims description 10
- 229940053031 botulinum toxin Drugs 0.000 claims description 10
- 108010014186 ras Proteins Proteins 0.000 claims description 10
- 102000016914 ras Proteins Human genes 0.000 claims description 10
- 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 claims description 9
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 claims description 9
- 102100031421 Ras-related protein Rap-2b Human genes 0.000 claims description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 9
- 235000003969 glutathione Nutrition 0.000 claims description 9
- 229960003180 glutathione Drugs 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 claims description 8
- 102100023362 Elongation factor 1-gamma Human genes 0.000 claims description 8
- 101001050451 Homo sapiens Elongation factor 1-gamma Proteins 0.000 claims description 8
- 108010057666 Transcription Factor CHOP Proteins 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 102100035473 2'-5'-oligoadenylate synthase-like protein Human genes 0.000 claims description 4
- 102100037618 Decapping and exoribonuclease protein Human genes 0.000 claims description 4
- 102100022901 Histone acetyltransferase KAT2A Human genes 0.000 claims description 4
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 claims description 4
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 claims description 4
- 101000597360 Homo sapiens 2'-5'-oligoadenylate synthase-like protein Proteins 0.000 claims description 4
- 101001046967 Homo sapiens Histone acetyltransferase KAT2A Proteins 0.000 claims description 4
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims description 4
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 102100037073 Cytoplasmic dynein 1 light intermediate chain 2 Human genes 0.000 claims description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 3
- 101000954691 Homo sapiens Cytoplasmic dynein 1 light intermediate chain 2 Proteins 0.000 claims description 3
- 101000881223 Homo sapiens Decapping and exoribonuclease protein Proteins 0.000 claims description 3
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 claims description 3
- 102100025460 Protein lin-28 homolog A Human genes 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 102100021246 DDIT3 upstream open reading frame protein Human genes 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 abstract description 10
- 230000005750 disease progression Effects 0.000 abstract description 10
- 239000000523 sample Substances 0.000 description 76
- 102100031298 Proteasome activator complex subunit 3 Human genes 0.000 description 51
- -1 TPM3 Proteins 0.000 description 48
- 101000705766 Homo sapiens Proteasome activator complex subunit 3 Proteins 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 37
- 108091008726 retinoic acid receptors α Proteins 0.000 description 35
- 238000003491 array Methods 0.000 description 26
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 description 20
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 description 20
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 description 20
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 description 18
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 description 18
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 description 18
- 230000007423 decrease Effects 0.000 description 18
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 description 12
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 101000828739 Homo sapiens SPATS2-like protein Proteins 0.000 description 11
- 102100023521 SPATS2-like protein Human genes 0.000 description 11
- 230000003827 upregulation Effects 0.000 description 11
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 description 10
- GXAFMKJFWWBYNW-OWHBQTKESA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC2CC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GXAFMKJFWWBYNW-OWHBQTKESA-N 0.000 description 10
- 101100202237 Danio rerio rxrab gene Proteins 0.000 description 10
- 101100309320 Danio rerio rxrga gene Proteins 0.000 description 10
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 description 10
- 101001082058 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 description 10
- 102100027303 Interferon-induced protein with tetratricopeptide repeats 2 Human genes 0.000 description 10
- 101150050070 RXRA gene Proteins 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 102100034270 Ankyrin repeat domain-containing protein 13A Human genes 0.000 description 9
- 101000780149 Homo sapiens Ankyrin repeat domain-containing protein 13A Proteins 0.000 description 9
- 101000628578 Homo sapiens Serine/threonine-protein kinase 16 Proteins 0.000 description 9
- 101001057127 Homo sapiens Transcription factor ETV7 Proteins 0.000 description 9
- 102100026758 Serine/threonine-protein kinase 16 Human genes 0.000 description 9
- 102100027263 Transcription factor ETV7 Human genes 0.000 description 9
- 101710120369 Tudor and KH domain-containing protein Proteins 0.000 description 9
- 102100036460 Tudor and KH domain-containing protein Human genes 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 8
- 101710103857 Proteasome activator complex subunit 3 Proteins 0.000 description 8
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 8
- 238000003498 protein array Methods 0.000 description 8
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 description 7
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102100039621 Epithelial-stromal interaction protein 1 Human genes 0.000 description 6
- 102100038584 F-BAR domain only protein 2 Human genes 0.000 description 6
- 101000814134 Homo sapiens Epithelial-stromal interaction protein 1 Proteins 0.000 description 6
- 101001030672 Homo sapiens F-BAR domain only protein 2 Proteins 0.000 description 6
- 101001011393 Homo sapiens Interferon regulatory factor 2 Proteins 0.000 description 6
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 6
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 6
- 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 description 6
- 101000625821 Homo sapiens TBC1 domain family member 2A Proteins 0.000 description 6
- 101000835634 Homo sapiens Tubulin-folding cofactor B Proteins 0.000 description 6
- 101150103227 IFN gene Proteins 0.000 description 6
- 102100029838 Interferon regulatory factor 2 Human genes 0.000 description 6
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 6
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 6
- 102100025574 Leukocyte immunoglobulin-like receptor subfamily A member 5 Human genes 0.000 description 6
- 108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 6
- 102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- 108090000854 Oxidoreductases Proteins 0.000 description 6
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 6
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 6
- 102100022090 Serine/threonine-protein kinase RIO2 Human genes 0.000 description 6
- 102100024767 TBC1 domain family member 2A Human genes 0.000 description 6
- 102000005937 Tropomyosin Human genes 0.000 description 6
- 108010030743 Tropomyosin Proteins 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 230000002438 mitochondrial effect Effects 0.000 description 6
- 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 5
- 101710164941 E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 description 5
- 101150042183 GIP3 gene Proteins 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 101100218338 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) aurO gene Proteins 0.000 description 5
- 101001132575 Homo sapiens Ras-related protein Rab-8B Proteins 0.000 description 5
- 101000754913 Homo sapiens Serine/threonine-protein kinase RIO2 Proteins 0.000 description 5
- 101000814514 Homo sapiens XIAP-associated factor 1 Proteins 0.000 description 5
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 5
- 102100033959 Ras-related protein Rab-8B Human genes 0.000 description 5
- 108010081734 Ribonucleoproteins Proteins 0.000 description 5
- 102000004389 Ribonucleoproteins Human genes 0.000 description 5
- 102100039488 XIAP-associated factor 1 Human genes 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 230000004547 gene signature Effects 0.000 description 5
- 108020001756 ligand binding domains Proteins 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 102100035197 Cerebral cavernous malformations 2 protein Human genes 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 101000737028 Homo sapiens Cerebral cavernous malformations 2 protein Proteins 0.000 description 4
- 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 description 4
- 101000739205 Homo sapiens Small G protein signaling modulator 3 Proteins 0.000 description 4
- 101000798942 Homo sapiens Target of Myb protein 1 Proteins 0.000 description 4
- 101000916523 Homo sapiens Zinc finger C4H2 domain-containing protein Proteins 0.000 description 4
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 4
- 101710119980 Macrophage migration inhibitory factor Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 102100032855 Sialoadhesin Human genes 0.000 description 4
- 102100037275 Small G protein signaling modulator 3 Human genes 0.000 description 4
- 102100034024 Target of Myb protein 1 Human genes 0.000 description 4
- 102100028880 Zinc finger C4H2 domain-containing protein Human genes 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 108010085650 interferon gamma receptor Proteins 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 102100022890 ATP synthase subunit beta, mitochondrial Human genes 0.000 description 3
- 101710134855 ATP synthase subunit beta, mitochondrial Proteins 0.000 description 3
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 3
- 101710120595 Cancer/testis antigen 2 Proteins 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102100027279 FAS-associated factor 1 Human genes 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 101000914654 Homo sapiens FAS-associated factor 1 Proteins 0.000 description 3
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 3
- 101000599458 Homo sapiens Protein phosphatase inhibitor 2 family member C Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010065958 Isopentenyl-diphosphate Delta-isomerase Proteins 0.000 description 3
- 102100027665 Isopentenyl-diphosphate Delta-isomerase 1 Human genes 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 102100032587 MOB-like protein phocein Human genes 0.000 description 3
- 101710168500 MOB-like protein phocein Proteins 0.000 description 3
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 3
- 102100037977 Protein phosphatase inhibitor 2 family member C Human genes 0.000 description 3
- 102000002278 Ribosomal Proteins Human genes 0.000 description 3
- 108010000605 Ribosomal Proteins Proteins 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 108060002430 dynein heavy chain Proteins 0.000 description 3
- 102000013035 dynein heavy chain Human genes 0.000 description 3
- 201000008319 inclusion body myositis Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 101150111214 lin-28 gene Proteins 0.000 description 3
- 150000004712 monophosphates Chemical class 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 238000010379 pull-down assay Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
- VDVJQFLGCFFFBP-UHFFFAOYSA-N 2,3-dihydropyrrole-1-carboxylic acid Chemical compound OC(=O)N1CCC=C1 VDVJQFLGCFFFBP-UHFFFAOYSA-N 0.000 description 2
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 2
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 2
- 102100030808 Elongation factor 1-delta Human genes 0.000 description 2
- 102100021823 Enoyl-CoA delta isomerase 2 Human genes 0.000 description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
- 101000920062 Homo sapiens Elongation factor 1-delta Proteins 0.000 description 2
- 101000896042 Homo sapiens Enoyl-CoA delta isomerase 2 Proteins 0.000 description 2
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 2
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 2
- 101001128963 Homo sapiens Protein Dr1 Proteins 0.000 description 2
- 101001131930 Homo sapiens Transcriptional activator protein Pur-beta Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 2
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 2
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 2
- 108010070511 Keratin-8 Proteins 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 102100032394 N-acetyltransferase 8 Human genes 0.000 description 2
- 101710092255 N-acetyltransferase 8 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 102100031227 Protein Dr1 Human genes 0.000 description 2
- 102100033947 Protein regulator of cytokinesis 1 Human genes 0.000 description 2
- 108050001955 Protein regulator of cytokinesis 1 Proteins 0.000 description 2
- 101150097162 SERPING1 gene Proteins 0.000 description 2
- 102100034549 Transcriptional activator protein Pur-beta Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000000730 protein immunoprecipitation Methods 0.000 description 2
- 238000001403 relative X-ray reflectometry Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- UOCLRXFKRLRMKV-UHFFFAOYSA-N trolnitrate phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.[O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O UOCLRXFKRLRMKV-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 102100028704 Acetyl-CoA acetyltransferase, cytosolic Human genes 0.000 description 1
- 102100040743 Alpha-crystallin B chain Human genes 0.000 description 1
- 241000428352 Amma Species 0.000 description 1
- 241001523209 Antissa Species 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 102100023006 Basic leucine zipper transcriptional factor ATF-like 2 Human genes 0.000 description 1
- 102100022529 Cadherin-19 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100021629 Calcium-binding protein 39-like Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 102100034560 Cytosol aminopeptidase Human genes 0.000 description 1
- 101710152531 Decapping and exoribonuclease protein Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100039369 Epidermal growth factor receptor substrate 15 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 102100024513 F-box only protein 6 Human genes 0.000 description 1
- LHABRXRGDLASIH-UHFFFAOYSA-N FIPI Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1CCNC(=O)C1=CC2=CC(F)=CC=C2N1 LHABRXRGDLASIH-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100027988 GTP-binding protein Rhes Human genes 0.000 description 1
- 102100031687 Galactose mutarotase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000837584 Homo sapiens Acetyl-CoA acetyltransferase, cytosolic Proteins 0.000 description 1
- 101000598552 Homo sapiens Acetyl-CoA acetyltransferase, mitochondrial Proteins 0.000 description 1
- 101000891982 Homo sapiens Alpha-crystallin B chain Proteins 0.000 description 1
- 101000903615 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 2 Proteins 0.000 description 1
- 101000899410 Homo sapiens Cadherin-19 Proteins 0.000 description 1
- 101000898517 Homo sapiens Calcium-binding protein 39-like Proteins 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 101000924389 Homo sapiens Cytosol aminopeptidase Proteins 0.000 description 1
- 101000812517 Homo sapiens Epidermal growth factor receptor substrate 15 Proteins 0.000 description 1
- 101001052796 Homo sapiens F-box only protein 6 Proteins 0.000 description 1
- 101000578396 Homo sapiens GTP-binding protein Rhes Proteins 0.000 description 1
- 101001066315 Homo sapiens Galactose mutarotase Proteins 0.000 description 1
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 description 1
- 101000998500 Homo sapiens Interferon-induced 35 kDa protein Proteins 0.000 description 1
- 101001082063 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 5 Proteins 0.000 description 1
- 101000969581 Homo sapiens MOB kinase activator 1A Proteins 0.000 description 1
- 101000956317 Homo sapiens Membrane-spanning 4-domains subfamily A member 4A Proteins 0.000 description 1
- 101001067396 Homo sapiens Phospholipid scramblase 1 Proteins 0.000 description 1
- 101000846284 Homo sapiens Pre-mRNA 3'-end-processing factor FIP1 Proteins 0.000 description 1
- 101000952073 Homo sapiens Probable ATP-dependent RNA helicase DDX60-like Proteins 0.000 description 1
- 101001035144 Homo sapiens Probable E3 ubiquitin-protein ligase HERC6 Proteins 0.000 description 1
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 description 1
- 101000613617 Homo sapiens Protein mono-ADP-ribosyltransferase PARP12 Proteins 0.000 description 1
- 101000686225 Homo sapiens Ras-related GTP-binding protein D Proteins 0.000 description 1
- 101000889087 Homo sapiens Spliceosome-associated protein CWC27 homolog Proteins 0.000 description 1
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 description 1
- 101000891620 Homo sapiens TBC1 domain family member 1 Proteins 0.000 description 1
- 101000830956 Homo sapiens Three-prime repair exonuclease 1 Proteins 0.000 description 1
- 101000662688 Homo sapiens Torsin-1B Proteins 0.000 description 1
- 101000713936 Homo sapiens Tudor domain-containing protein 7 Proteins 0.000 description 1
- 101000761740 Homo sapiens Ubiquitin/ISG15-conjugating enzyme E2 L6 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102100033273 Interferon-induced 35 kDa protein Human genes 0.000 description 1
- 102100027356 Interferon-induced protein with tetratricopeptide repeats 5 Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 1
- 108010066321 Keratin-14 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100021437 MOB kinase activator 1A Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100038556 Membrane-spanning 4-domains subfamily A member 4A Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100026741 Microsomal glutathione S-transferase 1 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 101100515452 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rca-1 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710085061 Orsellinic acid synthase Proteins 0.000 description 1
- 101710110277 Orsellinic acid synthase armB Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150089545 PYCR3 gene Proteins 0.000 description 1
- 102100034627 Phospholipid scramblase 1 Human genes 0.000 description 1
- 241001495084 Phylo Species 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 102100031755 Pre-mRNA 3'-end-processing factor FIP1 Human genes 0.000 description 1
- 102100037440 Probable ATP-dependent RNA helicase DDX60-like Human genes 0.000 description 1
- 102100039921 Probable E3 ubiquitin-protein ligase HERC6 Human genes 0.000 description 1
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
- 102100040923 Protein flightless-1 homolog Human genes 0.000 description 1
- 102100040845 Protein mono-ADP-ribosyltransferase PARP12 Human genes 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102100025002 Ras-related GTP-binding protein D Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100518046 Rattus norvegicus Oasl gene Proteins 0.000 description 1
- 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 description 1
- 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101001124028 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Non-structural maintenance of chromosome element 6 Proteins 0.000 description 1
- 108050002815 Serine/threonine-protein kinase Rio2 Proteins 0.000 description 1
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 1
- 102000001558 Sialic Acid Binding Ig-like Lectin 1 Human genes 0.000 description 1
- 102100039430 Spliceosome-associated protein CWC27 homolog Human genes 0.000 description 1
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100040238 TBC1 domain family member 1 Human genes 0.000 description 1
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 description 1
- 102100037453 Torsin-1B Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
- 102100036455 Tudor domain-containing protein 7 Human genes 0.000 description 1
- 102100024843 Ubiquitin/ISG15-conjugating enzyme E2 L6 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 108010008429 immunoglobulin-binding factors Proteins 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 108010074917 microsomal glutathione S-transferase-I Proteins 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108010008370 protein phosphatase 4 Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/56—IFN-alpha
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92422007P | 2007-05-03 | 2007-05-03 | |
| US92421907P | 2007-05-03 | 2007-05-03 | |
| US60/924,219 | 2007-05-03 | ||
| US60/924,220 | 2007-05-03 | ||
| US92458407P | 2007-05-21 | 2007-05-21 | |
| US60/924,584 | 2007-05-21 | ||
| US96018707P | 2007-09-19 | 2007-09-19 | |
| US60/960,187 | 2007-09-19 | ||
| US99617607P | 2007-11-05 | 2007-11-05 | |
| US99617407P | 2007-11-05 | 2007-11-05 | |
| US60/996,176 | 2007-11-05 | ||
| US60/996,174 | 2007-11-05 | ||
| US99621907P | 2007-11-06 | 2007-11-06 | |
| US60/996,219 | 2007-11-06 | ||
| US99682007P | 2007-12-06 | 2007-12-06 | |
| USPCT/US2007/24941 | 2007-12-06 | ||
| USPCT/US2007/24947 | 2007-12-06 | ||
| PCT/US2007/024941 WO2008070135A2 (en) | 2006-12-06 | 2007-12-06 | Methods of treating systemic lupus erythematosus |
| PCT/US2007/024947 WO2008070137A2 (en) | 2006-12-06 | 2007-12-06 | Interferon alpha-induced pharmacodynamic markers |
| US60/996,820 | 2007-12-06 | ||
| US696308P | 2008-02-08 | 2008-02-08 | |
| US61/006,963 | 2008-02-08 | ||
| PCT/US2008/062639 WO2008137835A2 (en) | 2007-05-03 | 2008-05-05 | Auto-antibody markers of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2685147A1 true CA2685147A1 (en) | 2008-11-13 |
Family
ID=39944226
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002685147A Abandoned CA2685147A1 (en) | 2007-05-03 | 2008-05-05 | Auto-antibody markers of autoimmune disease |
| CA002686861A Abandoned CA2686861A1 (en) | 2007-05-03 | 2008-05-05 | Interferon alpha-induced pharmacodynamic markers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002686861A Abandoned CA2686861A1 (en) | 2007-05-03 | 2008-05-05 | Interferon alpha-induced pharmacodynamic markers |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9181345B2 (enExample) |
| EP (2) | EP2076590A4 (enExample) |
| JP (3) | JP5411129B2 (enExample) |
| AU (2) | AU2008247395A1 (enExample) |
| CA (2) | CA2685147A1 (enExample) |
| WO (2) | WO2008137838A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2878025C (en) | 2008-01-18 | 2018-12-11 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| ES2613055T3 (es) * | 2009-09-03 | 2017-05-22 | Medimmune, Llc | Diagnóstico de interferón de tipo 1 |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| WO2012012717A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| KR20130041961A (ko) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액에서 질환 또는 상태의 특징을 검출하는 방법 |
| MX2013000917A (es) | 2010-07-23 | 2013-07-05 | Harvard College | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. |
| JP5998318B2 (ja) * | 2010-09-22 | 2016-09-28 | 国立大学法人 千葉大学 | 新規血管炎の検査方法および検査用試薬 |
| GB201017520D0 (en) * | 2010-10-15 | 2010-12-01 | Sense Proteomic Ltd | Biomarkers |
| CA2834203A1 (en) * | 2011-04-26 | 2012-11-01 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| AU2013204880B2 (en) * | 2011-04-26 | 2016-11-24 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| EP2923205B1 (en) * | 2012-11-23 | 2019-05-15 | Baerlecken, Niklas | Analysis for adult-onset still's disease |
| KR102216949B1 (ko) * | 2012-12-14 | 2021-02-22 | 민데라 코포레이션 | 바이오마커의 검출 및 취득을 위한 방법 및 디바이스 |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| EP4428251A3 (en) | 2014-09-11 | 2024-12-18 | Immunis.AI, Inc. | Methods of detecting prostate cancer |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| JP7374091B2 (ja) | 2017-08-22 | 2023-11-06 | サナバイオ， エルエルシー | 可溶性インターフェロン受容体およびその使用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EA202191133A1 (ru) * | 2018-10-26 | 2021-07-12 | Янссен Байотек, Инк. | Сигнатуры интерферона типа i и способы их применения |
| CN110747190B (zh) * | 2019-11-27 | 2021-03-09 | 浙江华睿生物技术有限公司 | 一种马来酸水合酶突变体及其应用 |
| WO2025062016A2 (en) * | 2023-09-22 | 2025-03-27 | Merck Patent Gmbh | Biomarkers for tlr inhibitor treatment |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| FR2692168B1 (fr) | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| AU696455C (en) | 1994-03-23 | 2006-03-02 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
| US5972901A (en) | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
| EP0989849A2 (en) | 1997-06-13 | 2000-04-05 | The Johns Hopkins University School Of Medicine | Therapeutic nanospheres |
| US20050008683A1 (en) * | 2000-06-29 | 2005-01-13 | Becton Dickinson And Company | Method for delivering interferons to the intradermal compartment |
| US20040265874A1 (en) * | 2000-10-17 | 2004-12-30 | Bio-Rad Laboratories, Inc. | Pattern recognition method for diagnosis of systemic autoimmune diseases |
| EP2236156A3 (en) * | 2001-01-09 | 2011-01-05 | Baylor Research Institute | Methods for treating and diagnosing Psoriasis |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| WO2003046008A1 (en) * | 2001-11-30 | 2003-06-05 | Innogenetics N.V. | Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma |
| PT1569696E (pt) * | 2002-11-21 | 2010-11-11 | Bayhill Therapeutics Inc | Composições para prevenção e tratamento de esclerose múltipla e diabetes de tipo 1 |
| JP2007503838A (ja) * | 2003-09-05 | 2007-03-01 | ジーティーシー バイオセラピューティクス， インコーポレイティド | トランスジェニック動物の乳汁中での融合タンパク質の産生方法 |
| DK1711207T3 (da) * | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| CA2597265C (en) * | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| US20070117105A1 (en) * | 2005-05-12 | 2007-05-24 | Crow Mary K | Interferon assay |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| EP1945800B1 (en) * | 2005-08-05 | 2012-03-14 | Genentech, Inc. | Methods and compositions for detecting autoimmune disorders |
| US7608395B2 (en) * | 2005-09-15 | 2009-10-27 | Baylor Research Institute | Systemic lupus erythematosus diagnostic assay |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
| US20110287022A1 (en) * | 2008-06-20 | 2011-11-24 | Medlmmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| ES2613055T3 (es) * | 2009-09-03 | 2017-05-22 | Medimmune, Llc | Diagnóstico de interferón de tipo 1 |
-
2008
- 2008-05-05 CA CA002685147A patent/CA2685147A1/en not_active Abandoned
- 2008-05-05 EP EP08769294A patent/EP2076590A4/en not_active Withdrawn
- 2008-05-05 EP EP08747639A patent/EP2068924A4/en not_active Withdrawn
- 2008-05-05 CA CA002686861A patent/CA2686861A1/en not_active Abandoned
- 2008-05-05 WO PCT/US2008/062646 patent/WO2008137838A2/en not_active Ceased
- 2008-05-05 WO PCT/US2008/062639 patent/WO2008137835A2/en not_active Ceased
- 2008-05-05 AU AU2008247395A patent/AU2008247395A1/en not_active Abandoned
- 2008-05-05 JP JP2010506715A patent/JP5411129B2/ja not_active Expired - Fee Related
- 2008-05-05 JP JP2010506714A patent/JP2010526107A/ja not_active Withdrawn
- 2008-05-05 AU AU2008247398A patent/AU2008247398B2/en not_active Ceased
-
2011
- 2011-11-07 US US13/290,850 patent/US9181345B2/en active Active
-
2013
- 2013-11-07 JP JP2013230753A patent/JP2014064577A/ja active Pending
-
2014
- 2014-09-23 US US14/494,439 patent/US20150132313A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9181345B2 (en) | 2015-11-10 |
| EP2076590A2 (en) | 2009-07-08 |
| CA2686861A1 (en) | 2008-11-13 |
| AU2008247398A8 (en) | 2010-01-21 |
| AU2008247398B2 (en) | 2013-10-10 |
| JP2010526107A (ja) | 2010-07-29 |
| JP5411129B2 (ja) | 2014-02-12 |
| EP2076590A4 (en) | 2011-06-01 |
| JP2014064577A (ja) | 2014-04-17 |
| WO2008137835A2 (en) | 2008-11-13 |
| US20150132313A1 (en) | 2015-05-14 |
| WO2008137838A3 (en) | 2008-12-31 |
| AU2008247395A1 (en) | 2008-11-13 |
| EP2068924A4 (en) | 2011-07-20 |
| EP2068924A2 (en) | 2009-06-17 |
| JP2010527917A (ja) | 2010-08-19 |
| WO2008137838A2 (en) | 2008-11-13 |
| AU2008247398A1 (en) | 2008-11-13 |
| WO2008137835A3 (en) | 2008-12-24 |
| US20120219555A1 (en) | 2012-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9181345B2 (en) | Methods of treating lupus | |
| AU2007327995B2 (en) | Interferon alpha-induced pharmacodynamic markers | |
| JP4711963B2 (ja) | 炎症性疾患および自己免疫疾患を診断、治療および評価するためにサイトカインアッセイを用いる方法 | |
| CN101999001B (zh) | 疾病标志物及其用途 | |
| AU2014329535B2 (en) | Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare | |
| TW201307845A (zh) | 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法 | |
| AU2014329535A1 (en) | Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare | |
| US20100266610A1 (en) | Auto-antibody markers of autoimmune disease | |
| CN101594882A (zh) | 干扰素α诱导的药代动力学标记物 | |
| WO2009155559A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| Calderón-Gómez et al. | BASIC AND TRANSLATIONAL—ALIMENTARY TRACT | |
| Gold | Characterisation of inflammatory markers and the Th1/Th2 response in localized scleroderma | |
| Ryder | FoxP3 mRNA splice forms in arthritis patients | |
| HK1140406A (en) | Interferon alpha-induced pharmacodynamic markers | |
| AU2014200127A1 (en) | Interferon alpha-induced pharmacodynamic markers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130506 |